FDA launches contest to develop mobile app technology to fight opioid overdose epidemic

FDA logo

The FDA launched a public contest to develop new technologies that can be used with mobile apps to stem the rising epidemic of opioid overdoses in the U.S.

Called the 2016 Naloxone App Competition, the contest is asking people with expertise in tech fields as well as public health advocates and clinical researchers to come up with a mobile phone app that can connect opioid users experiencing an overdose with the nearest location that has the prescription drug naloxone, the antidote for an opioid overdose.

The winner will receive a $40,000 award and may apply for National Institute on Drug Abuse Small Business Innovation Research grants to further develop their concepts and to develop data to evaluate their real-world impact, the FDA said.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

“With a dramatic increase in the number of opioid overdose deaths in the U.S., there’s a vital need to harness the power of new technologies to quickly and effectively link individuals experiencing an overdose … with someone who carries and can administer the life-saving medication,” Dr. Robert Califf, the agency’s commissioner, said in a statement.

The competition is being held with support from the National Institute on Drug Abuse and the Substance Abuse and Mental Health Services Administration.

According to government statistics, about 28,000 people died in the U.S. in 2014 from abusing prescription opioids such as oxycodone, hydrocodone and morphine and illicit opioids, such as heroin and illegally produced fentanyl. That is triple the number of such deaths recorded since 1999.

Suggested Articles

The respiratory care company Vyaire Medical has brought on a new CEO, Gaurav Agarwal, following a year of new product launches.

Precision oncology firm Notable Labs is launching its first self-sponsored clinical trial, designed from the ground up to help validate its platform.

Inotrem and Roche’s diagnostics division have upgraded their years-long collaboration on a plasma test for septic shock, with a new worldwide deal.